CN111093657A - 用于治疗视网膜疾病的光感受器基因调节剂光调节素3 - Google Patents

用于治疗视网膜疾病的光感受器基因调节剂光调节素3 Download PDF

Info

Publication number
CN111093657A
CN111093657A CN201880051862.3A CN201880051862A CN111093657A CN 111093657 A CN111093657 A CN 111093657A CN 201880051862 A CN201880051862 A CN 201880051862A CN 111093657 A CN111093657 A CN 111093657A
Authority
CN
China
Prior art keywords
retina
retinal
compound
subject
rod
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880051862.3A
Other languages
English (en)
Chinese (zh)
Inventor
T·A·雷
P·纳卡穆拉
A·施穆丘克
S·唐
S·丁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
J David Gladstone Institutes
Original Assignee
University of Washington
J David Gladstone Institutes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington, J David Gladstone Institutes filed Critical University of Washington
Publication of CN111093657A publication Critical patent/CN111093657A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CN201880051862.3A 2017-08-10 2018-08-10 用于治疗视网膜疾病的光感受器基因调节剂光调节素3 Pending CN111093657A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762543782P 2017-08-10 2017-08-10
US62/543782 2017-08-10
PCT/US2018/046272 WO2019032999A1 (en) 2017-08-10 2018-08-10 PHOTORECEPTOR GENE MODULATOR PHOTOREGULIN 3 FOR THE TREATMENT OF RETINAL DISEASE

Publications (1)

Publication Number Publication Date
CN111093657A true CN111093657A (zh) 2020-05-01

Family

ID=65272549

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880051862.3A Pending CN111093657A (zh) 2017-08-10 2018-08-10 用于治疗视网膜疾病的光感受器基因调节剂光调节素3

Country Status (8)

Country Link
US (1) US20200368234A1 (enExample)
EP (1) EP3664801A4 (enExample)
JP (1) JP2020530459A (enExample)
CN (1) CN111093657A (enExample)
AU (1) AU2018313990A1 (enExample)
CA (1) CA3072175A1 (enExample)
MX (1) MX2020001274A (enExample)
WO (1) WO2019032999A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11241460B2 (en) 2013-03-15 2022-02-08 Astellas Institute For Regenerative Medicine Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160015783A1 (en) * 2013-03-01 2016-01-21 The Schepens Eye Research Institute, Inc. Methods for modulating development and function of photoreceptor cells
CN105343107A (zh) * 2015-12-03 2016-02-24 上海中医药大学附属岳阳中西医结合医院 雷公藤红素在制备防治视网膜退行性改变相关疾病药物中的应用
WO2016160718A1 (en) * 2015-03-27 2016-10-06 University Of Washington Methods for treatment of retinal disease by photoreceptor gene expression modulation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160015783A1 (en) * 2013-03-01 2016-01-21 The Schepens Eye Research Institute, Inc. Methods for modulating development and function of photoreceptor cells
WO2016160718A1 (en) * 2015-03-27 2016-10-06 University Of Washington Methods for treatment of retinal disease by photoreceptor gene expression modulation
CN105343107A (zh) * 2015-12-03 2016-02-24 上海中医药大学附属岳阳中西医结合医院 雷公藤红素在制备防治视网膜退行性改变相关疾病药物中的应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
《PUBCHEM 数据库》: "AID 651849 - SID 152164087", 《PUBCHEM 数据库》 *

Also Published As

Publication number Publication date
US20200368234A1 (en) 2020-11-26
EP3664801A4 (en) 2021-06-23
WO2019032999A1 (en) 2019-02-14
EP3664801A1 (en) 2020-06-17
MX2020001274A (es) 2020-09-22
CA3072175A1 (en) 2019-02-14
AU2018313990A1 (en) 2020-02-27
JP2020530459A (ja) 2020-10-22

Similar Documents

Publication Publication Date Title
Wang et al. The mitophagy pathway and its implications in human diseases
Kole et al. Activating transcription factor 3 (ATF3) protects retinal ganglion cells and promotes functional preservation after optic nerve crush
Chawla et al. Neuronal activity‐dependent nucleocytoplasmic shuttling of HDAC4 and HDAC5
Colussi et al. Nitric oxide deficiency determines global chromatin changes in Duchenne muscular dystrophy
Roberti et al. Nerve growth factor modulation of retinal ganglion cell physiology
Kato et al. Endocannabinoid‐dependent plasticity at spinal nociceptor synapses
Ng et al. Genetic or pharmacological activation of the Drosophila PGC-1α ortholog spargel rescues the disease phenotypes of genetic models of Parkinson's disease
US10849904B2 (en) Methods for treatment of retinal disease by photoreceptor gene expression modulation
US20250057868A1 (en) Compositions and methods of modulating hif-2a to improve muscle generation and repair
Liu et al. Prolyl-4-hydroxylases inhibitor stabilizes HIF-1α and increases mitophagy to reduce cell death after experimental retinal detachment
Szarka et al. The role of gap junctions in cell death and neuromodulation in the retina
Carrella et al. miR‐181a/b downregulation: A mutation‐independent therapeutic approach for inherited retinal diseases
WO2016205631A1 (en) Serotonin 2c receptor antagonists to prevent and treat stress-related trauma disorders
Feng et al. Trilobatin attenuates cerebral ischaemia/reperfusion‐induced blood–brain barrier dysfunction by targeting matrix metalloproteinase 9: The legend of a food additive
D'Angelo et al. Signal transduction pathways involved in PPARβ/δ‐induced neuronal differentiation
Xu et al. Molecular mechanism and therapy application of necrosis during myocardial injury
Carreño et al. Brain‐derived neurotrophic factor‐tyrosine kinase B pathway mediates NMDA receptor NR2B subunit phosphorylation in the supraoptic nuclei following progressive dehydration
Wu et al. The antioxidant effect of tetrahedral framework nucleic acid‐based delivery of small activating RNA targeting DJ‐1 on retinal oxidative stress injury
Mu et al. Up-regulation of GPR139 in the medial septum ameliorates cognitive impairment in two mouse models of Alzheimer’s disease
Zhou et al. Molecular insights into tau pathology and its therapeutic strategies in Alzheimer's disease
Yadav et al. Methotrexate negatively acts on inflammatory responses triggered in Drosophila larva with hyperactive JAK/STAT pathway
CN111093657A (zh) 用于治疗视网膜疾病的光感受器基因调节剂光调节素3
Wong et al. A Novel RANKL‐Targeted Furoquinoline Alkaloid Ameliorates Bone Loss in Ovariectomized Osteoporosis through Inhibiting the NF‐κB Signal Pathway and Reducing Reactive Oxygen Species
AU2928199A (en) Method for the treatment of diseases or disorders of the inner ear
Gu et al. Sprouty1 regulates neuritogenesis and survival of cortical neurons

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200501